Business UpdateJun 16, 2026, 07:01 AM
Evogene Highlights AI-First Small Molecule Discovery Platform
AI Summary
Evogene Ltd. presented its proprietary generative AI engine, ChemPass AI, designed for the discovery and optimization of small molecules. The technology aims to revolutionize the pharmaceutical and ag-chemical industries by generating novel, highly potent compounds optimized across multiple parameters. The company emphasizes its ability to overcome limitations of traditional methods, such as confined chemical space and lack of simultaneous multi-parameter optimization, through its three-step process: PointHit, ActiveSearch, and LeadOp GPT. This AI-first approach is expected to increase the probability of success in developing new products.
Key Highlights
- Evogene utilizes its proprietary generative AI engine, ChemPass AI, for small molecule discovery and optimization.
- The AI engine generates novel, highly potent small molecules optimized across multiple parameters for pharmaceutical and ag-chemical industries.
- ChemPass AI addresses limitations of current methods by exploring new chemical space and performing multi-parameter optimization simultaneously.
- The platform employs a three-step process: PointHit for rapid screening, ActiveSearch for lead optimization, and LeadOp GPT for novel molecule generation.
- LeadOp GPT is an in-house built AI engine trained on a curated 38 billion molecule database, developed in collaboration with Google Cloud.
- The technology aims to increase the probability of success in drug discovery by generating diverse, synthesizable, and active compounds.
- Evogene highlights growing collaborations for a diverse pipeline of drug candidates in pharma and ag-chem.
Price Impact
More from EVGN